ScienBio Technology Obtains Patent for Manufacturing Method of Cross-linked Hyaluronic Acid Gel Containing Special Corticosteroid
ScienBio Technology announced that it has received patent approval from Taiwan's Intellectual Property Office for its invention titled 'Manufacturing Method for Cross-linked Hyaluronic Acid Gel Containing Special Corticosteroid and Cross-linked Hyaluronic Acid Gel.' This patent is expected to contribute to new product development and enhance the company's competitiveness.
📋 Article Processing Timeline
- 📰 Published: April 15, 2026 at 09:00
- 🔍 Collected: April 16, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: April 19, 2026 at 02:50 (66h 50m after Collected)
1. Date of event: 115/04/15
2. Company Name: ScienBio Technology Co., Ltd.
3. Relationship with parent company: Parent Company
4. Shareholding ratio: Not applicable
5. Reason for event: The company's patent application 'Manufacturing Method for Cross-linked Hyaluronic Acid Gel Containing Special Corticosteroid and Cross-linked Hyaluronic Acid Gel,' filed with Taiwan's Intellectual Property Office (TIPO), has been reviewed and approved, and a patent grant notice has been received. Invention Patent Application No: 113132817.
6. Measures taken: Announcement of this disclosure.
7. Other matters to be disclosed (If the subject of the event or resolution is a publicly issuing company or above, this material information also meets the requirements of Article 7, Paragraph 9 of the Securities Transaction Act Enforcement Rules for matters that have a significant impact on shareholder equity or security prices): Can be used for new product development or improvement of product efficacy, increasing product diversity, and enhancing company competitiveness.
Keywords: Material Information
2. Company Name: ScienBio Technology Co., Ltd.
3. Relationship with parent company: Parent Company
4. Shareholding ratio: Not applicable
5. Reason for event: The company's patent application 'Manufacturing Method for Cross-linked Hyaluronic Acid Gel Containing Special Corticosteroid and Cross-linked Hyaluronic Acid Gel,' filed with Taiwan's Intellectual Property Office (TIPO), has been reviewed and approved, and a patent grant notice has been received. Invention Patent Application No: 113132817.
6. Measures taken: Announcement of this disclosure.
7. Other matters to be disclosed (If the subject of the event or resolution is a publicly issuing company or above, this material information also meets the requirements of Article 7, Paragraph 9 of the Securities Transaction Act Enforcement Rules for matters that have a significant impact on shareholder equity or security prices): Can be used for new product development or improvement of product efficacy, increasing product diversity, and enhancing company competitiveness.
Keywords: Material Information